Castro-Vazquez, D.; Lamana, A.; Arribas-Castaño, P.; Gutiérrez-Cañas, I.; Villanueva-Romero, R.; Pérez-García, S.; Martínez, C.; Juarranz, Y.; Fernández de Córdoba, S.; González-Álvaro, I.;
et al. The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis. Biomedicines 2021, 9, 1880.
https://doi.org/10.3390/biomedicines9121880
AMA Style
Castro-Vazquez D, Lamana A, Arribas-Castaño P, Gutiérrez-Cañas I, Villanueva-Romero R, Pérez-García S, Martínez C, Juarranz Y, Fernández de Córdoba S, González-Álvaro I,
et al. The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis. Biomedicines. 2021; 9(12):1880.
https://doi.org/10.3390/biomedicines9121880
Chicago/Turabian Style
Castro-Vazquez, David, Amalia Lamana, Paula Arribas-Castaño, Irene Gutiérrez-Cañas, Raúl Villanueva-Romero, Selene Pérez-García, Carmen Martínez, Yasmina Juarranz, Sara Fernández de Córdoba, Isidoro González-Álvaro,
and et al. 2021. "The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis" Biomedicines 9, no. 12: 1880.
https://doi.org/10.3390/biomedicines9121880
APA Style
Castro-Vazquez, D., Lamana, A., Arribas-Castaño, P., Gutiérrez-Cañas, I., Villanueva-Romero, R., Pérez-García, S., Martínez, C., Juarranz, Y., Fernández de Córdoba, S., González-Álvaro, I., Gomariz, R. P., & Carrión, M.
(2021). The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis. Biomedicines, 9(12), 1880.
https://doi.org/10.3390/biomedicines9121880
